Economic evaluation examines cost-effectiveness of pembrolizumab in locally advanced head and neck cancer, highlighting implications for treatment.
This economic evaluation evaluates the cost-effectiveness of perioperative pembrolizumab plus standard of care (SOC) for the treatment of locally advanced head and neck squamous cell carcinoma compared with SOC alone using Canada as a case study.
No takes yet. Share an insight, caveat, or question.
Noel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: